DUALITY ADVISERS, LP - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 182 filers reported holding BRIDGEBIO PHARMA INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.3%.

Quarter-by-quarter ownership
DUALITY ADVISERS, LP ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$1,296,244
+86.3%
49,156
+17.1%
0.16%
+98.7%
Q1 2023$695,896
-80.7%
41,972
-80.6%
0.08%
-79.8%
Q4 2021$3,607,000
+114.1%
216,254
+501.4%
0.39%
+203.1%
Q3 2021$1,685,000
+7.2%
35,956
+39.5%
0.13%
-7.9%
Q2 2021$1,572,00025,7820.14%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 3,835,722$103,449,00044.18%
Kohlberg Kravis Roberts & Co. L.P. 36,900,661$995,211,00012.26%
SC US (TTGP), LTD. 2,544,738$68,632,0004.69%
Cormorant Asset Management, LP 2,780,885$75,000,0004.31%
Perceptive Advisors 6,706,268$180,868,0004.15%
VIKING GLOBAL INVESTORS LP 26,620,991$717,968,0003.22%
Hillhouse Capital Management 2,035,790$54,905,0001.75%
Alpine Group USVI, LLC 20,000$539,0001.70%
HHLR ADVISORS, LTD. 2,352,900$63,458,0001.42%
SCGE MANAGEMENT, L.P. 588,235$15,865,0000.79%
View complete list of BRIDGEBIO PHARMA INC shareholders